Fig. 7.

Anti‐TGF‐β antibody 1D11 decreases bone formation rate/body surface (BFR/BS) and mineral apposition rate (MAR) in mice with osteogenesis imperfecta (OI) relative to 13C4 control at three‐times weekly dosing for 8 weeks in OI mice. BFR/BS and MAR are lower in OI compared with WT mice, both treated with 13C4 control, n = 8, 5, 5, and 8 for groups 1–4, respectively. Mean ± SD and asterisk(s) denote statistically significant difference compared with OI 13C4. ^a0.01 < p < 0.05. ^b0.001 < p < 0.01. ^c0.0001 < p < 0.001. ^d p < 0.0001. All doses 5 mg/kg ip.